

**Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes**
Abbreviations Used in Presentation

Transplant-Eligible Patients

VRd or RVd	Bortezomib/lenalidomide/dexamethasone
KRd	Carfilzomib/lenalidomide/dexamethasone
DARA-RVd	Daratumumab/lenalidomide/bortezomib/dexamethasone
IRd	Ixazomib/lenalidomide/dexamethasone
VCD	Bortezomib/cyclophosphamide/dexamethasone
PAD	Bortezomib/doxorubicin/dexamethasone
KCd	Carfilzomib/cyclophosphamide/dexamethasone
ICd	Ixazomib/cyclophosphamide/dexamethasone
VTd	Bortezomib/thalidomide/dexamethasone
CRd	Cyclophosphamide/lenalidomide/dexamethasone
DARA-KRd	Daratumumab/carfilzomib/lenalidomide/dexamethasone
DARA-VCd	Daratumumab/bortezomib/cyclophosphamide/dexamethasone
DARA-VTd	Daratumumab/bortezomib/thalidomide/dexamethasone
VTd-PACE	Bortezomib/thalidomide/dexamethasone/cisplatin/doxorubicin/ cyclophosphamide/etoposide



**Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes**
Abbreviations Used in Presentation

Transplant-Ineligible Patients

DRd	Daratumumab/lenalidomide/dexamethasone
KRd	Carfilzomib/lenalidomide/dexamethasone
DVd	Daratumumab/bortezomib/dexamethasone
IRd	Ixazomib/lenalidomide/dexamethasone
VCD	Bortezomib/cyclophosphamide/dexamethasone
Rd	Lenalidomide/dexamethasone
KCD	Carfilzomib/cyclophosphamide/dexamethasone
RVd	Bortezomib/lenalidomide/dexamethasone
D-VMP	Daratumumab/bortezomib/melphalan/prednisone
D-VCd	Daratumumab/bortezomib/cyclophosphamide/dexamethasone
Vd	Bortezomib/dexamethasone
CRd	Cyclophosphamide/lenalidomide/dexamethasone
VRD-LITE	Bortezomib/lenalidomide/dexamethasone
VMP	Bortezomib/melphalan, prednisone
MPT	Melphalan/prednisone/thalidomide



**Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes**
Abbreviations Used in Presentation

